PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
36.20
+0.22 (+0.61%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close35.98
Open35.93
Bid35.81 x 1200
Ask36.43 x 1300
Day's Range35.75 - 36.33
52 Week Range29.83 - 36.60
Volume14,019,661
Avg. Volume17,060,540
Market Cap215.29B
Beta1.09
PE Ratio (TTM)26.48
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.28 (3.52%)
Ex-Dividend Date2017-11-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • This hot trade is about to get even hotter: Trader
    CNBC Videos13 hours ago

    This hot trade is about to get even hotter: Trader

    The “Fast Money” traders discuss the health care sector seeing a pop and where it could go from here.

  • Reuters52 minutes ago

    Reckitt to restructure after sales growth evaporates

    Reckitt Benckiser has decided to split its business into two units - consumer healthcare and home and hygiene products - the British consumer goods company said on Wednesday, after warning that there would be no growth in sales this year. Reckitt said to help boost performance it would operate from two business units from the start of 2018. Chief Executive Rakesh Kapoor told Reuters the restructuring decision was made after the acquisition in June of baby milk maker Mead Johnson, its biggest ever acquisition.

  • Reuters4 hours ago

    Reckitt Benckiser to form two business units for better focus

    Reckitt Benckiser (RB.L) plans to reorganise its business into two distinct units, one for health and the other for hygiene and home products, as it tries to improve its flagging performance. The maker of Durex condoms, Nurofen tablets and Dettol cleaners announced the restructuring on Wednesday, along with its third-quarter sales figures. The British company made the decision to restructure after its June acquisition of U.S. baby formula maker Mead Johnson, which will account for roughly half of the larger health unit's sales.

  • Reckitt Overhauls Business as CEO Kapoor Looks Beyond Worst Year
    Bloomberg4 hours ago

    Reckitt Overhauls Business as CEO Kapoor Looks Beyond Worst Year

    Reckitt Benckiser Group Plc separated its home-care and health businesses as Chief Executive Officer Rakesh Kapoor pins hopes for growth on brands such as Durex condoms and Enfamil baby formula after a ...

  • Forbes7 hours ago

    Tiny Ignyta's Lung Cancer Drug Bested Pfizer's. Probably. Will We Ever Know For Sure?

    Results of a 32-patient study of a drug made by Ignyta Pharmaceuticals, a San Diego-based drugmaker, are a best case scenario for the company. The drug shrank tumors in 79% of patients and kept workingabout 10 months longer than the current drug, Pfizer’s Xalkori, did in earlier clinical trials.

  • Aerie (AERI) Up on FDA Review Committee Result for Rhopressa
    Zacks12 hours ago

    Aerie (AERI) Up on FDA Review Committee Result for Rhopressa

    Shares of Aerie Pharmaceuticals, Inc. (AERI) have moved up 15.8% in the last week on positive news for its lead drug, Rhopressa.

  • J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales
    Zacks20 hours ago

    J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales

    J&J (JNJ) reported better-than-expected third-quarter 2017 results and raised its 2017 sales and profit outlook.

  • Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
    Zacks21 hours ago

    Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen

    Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen

  • Forbes22 hours ago

    The Blockbuster That Wasn't -- A CETP Inhibitor Post-Mortem

    The quest for the “holy grail” of cardiovascular therapy - a drug that dramatically lowered LDL-c and raised HDL-c and which would hopefully reverse atherosclerosis - has ended ignominiously.

  • Pharma Industry Outlook - October 2017
    Zacks2 days ago

    Pharma Industry Outlook - October 2017

    Pharma Industry Outlook - October 2017

  • Investopedia2 days ago

    How Stock Investors Can Profit Big From Spinoffs

    Spinning Rich Profits: Spinoffs as a group have posted total returns of nearly 300% over 10 years

  • Forbes2 days ago

    The Cost Of Developing Drugs Is Insane. That Paper That Says Otherwise Is Insanely Bad

    The pharmaceutical industry puts the cost of bringing a medicine from invention to pharmacy shelves at $2.7 billion. A new paper says it is 'just' $648 million. Unfortunately for pharmaceutical investors and people fighting to control drug prices, alike, the new number doesn’t stand up scrutiny.

  • The Wall Street Journal2 days ago

    [$$] Drugstore Favorites May Be Catching the Common Consumer Cold

    Customers may be starting to shop for over-the-counter drugs in the same way they shop for groceries—with a keener eye for cost and content—and this could be painful for consumer-health companies.

  • TheStreet.com3 days ago

    Pfizer Consumer Unit Worth as Much as $14 Billion

    A deal would give the company capital to do more deals but the decision also keeps the company's recently scratched plans to split into two separate companies alive. The division itself had about $3.4 ...

  • Motley Fool4 days ago

    Earnings Season Preview: 2 Things to Watch For in Healthcare

    J&J is the lead-off hitter, and its Remicade results will tell us a lot. So will the biosimilar numbers from Pfizer.

  • Motley Fool4 days ago

    Pfizer Says It's Pondering a Big Sale

    The pharmaceutical major announced it's thinking about finding a buyer for its consumer healthcare unit.

  • 5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings
    Zacks5 days ago

    5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings

    The pharma/biotech sector has a number of things going in its favor.

  • Spin-Off ETF: Can the Outperformance Continue?
    Zacks5 days ago

    Spin-Off ETF: Can the Outperformance Continue?

    Spin-off activities picked up pace in the United States.

  • Market Realist5 days ago

    Behind Eli Lilly’s October Analyst Recommendations

    So far in October, of the 22 analysts covering Eli Lilly (LLY), four have suggested a “strong buy,” while ten analysts have suggested a “buy.”

  • Barrons.com5 days ago

    Pharma Sales Could Be Chilled by Hurricane Damage

    Pharmaceutical third-quarter earnings are nearly upon us, and Guggenheim's Tony Butler and Allen Cha provide their thoughts on the upcoming results. Butler and Cha write that the hurricanes are a factor ...

  • Barrons.com5 days ago

    Pfizer: Could a Big Merger Move the Needle?

    T here’s been speculation about whether or not Pfizer (PFE) is planning to make a large acquisition, and Guggenheim’s Tony Butler takes on the question, writing that a smart deal could expand the pharma giant’s multiple. Butler notes that Pfizer’s management has stated that it’s aware of the need to create shareholder value, and he believes that the outcome hinges on a number of factors, including any potential tax reform/cash repatriation holiday, as well as clinical trial results. At the moment, Pfizer has a joint venture with Merck (MRK) to develop Bavencio, a PD-L1 antibody, but Butler wonders if it might be willing to step back if the data isn’t supportive, and if it might be willing to acquire a company with a different, PD-1 antibody—again if the data bears it out.

  • Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback
    Zacks5 days ago

    Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback

    Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.

  • Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy
    InvestorPlace5 days ago

    Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy

    Markets barely reacted when Gilead Sciences Inc. (NASDAQ:GILD) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion. The slowdown in Gilead’s HCV business is starting to come to an end. The HCV segment will continue adding meaningfully to Gilead’s cash flow, which is money it needs to fund the Kite acquisition.

  • Motley Fool5 days ago

    2 Reasons Pfizer Is on Our Minds Today

    First, it raised some spinoff speculation. Second, it's in an intriguing tussle with J&J that could affect the biosimilars market for everyone.

  • Barrons.com6 days ago

    [$$] Pfizer Seen Mulling Options

    Credit Suisse We are not surprised by Pfizer’s announcement [Tuesday] morning that they are exploring strategic options for their Consumer Healthcare business. Based on our recent conversations with the company, it had become clear to us that Pfizer (PFE) management does not see this business as part of their long-term innovative core. After speaking with the company again today and based on their previous transactions, we assume Pfizer will take their usual time and care in exploring all options.